Methotrexate or retinoids: Which one poses lower cardiovascular risks in psoriasis?

Key clinical point: Patients with psoriasis receiving methotrexate therapy were less prone to develop composite cardiovascular outcomes than those receiving retinoids.

Major finding: Methotrexate vs. retinoids was associated with lower risks for composite cardiovascular outcomes (adjusted hazard ratio [aHR], 0.84; 95% confidence interval [CI], 0.76-0.94) and all-cause mortality (aHR, 0.75; 95% CI, 0.66-0.85).

Study details: This was a retrospective nationwide cohort study that included 19,797 patients with psoriasis, of which 13,777 and 6,020 patients received MTX and retinoids, respectively.

,

Disclosures: This study was supported by the Taiwan Ministry of Science and Technology. The authors declared no potential conflict of interests.

Source: Tsai MH et al. Clin Epidemiol. 2021 Aug 11. doi: 10.2147/CLEP.S305126.